Product
NTQ1062 with Fulvestrant
1 clinical trial
1 indication
Indication
HR Positive/HER-2 Negative Breast CancerClinical trial
A Phase Ib/Ⅱ Study of Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of NTQ1062 Tablets in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01